Therapeutic Innovation & Regulatory Science

Scope & Guideline

Elevating Standards in Pharmacology and Healthcare Innovation

Introduction

Welcome to your portal for understanding Therapeutic Innovation & Regulatory Science, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN2168-4790
PublisherSPRINGER HEIDELBERG
Support Open AccessNo
CountryUnited States
TypeJournal
Converge1970, 1972, from 1974 to 2006, from 2008 to 2011, from 2013 to 2024
AbbreviationTHER INNOV REGUL SCI / Ther. Innov. Regul. Sci.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY

Aims and Scopes

The journal 'Therapeutic Innovation & Regulatory Science' focuses on advancing the understanding and practice of drug and medical device development, evaluation, and regulation. It aims to bridge the gap between scientific research and regulatory frameworks, ensuring that innovative therapeutics are effectively developed and brought to market while maintaining safety and efficacy standards.
  1. Drug Development and Regulation:
    The journal emphasizes research related to the regulatory processes surrounding drug development, including the evaluation of clinical trial designs, regulatory pathways, and post-marketing surveillance.
  2. Real-World Evidence and Pharmacovigilance:
    A significant focus is placed on leveraging real-world evidence for regulatory decisions, monitoring drug safety, and improving pharmacovigilance practices across diverse healthcare settings.
  3. Innovative Clinical Trial Designs:
    The journal explores advancements in clinical trial methodologies, including adaptive designs, seamless trials, and the use of external controls to enhance the efficiency and effectiveness of drug development.
  4. Patient-Centric Approaches:
    There is a consistent emphasis on incorporating patient perspectives, preferences, and experiences into the drug development process, fostering a more patient-centered approach to therapeutic innovation.
  5. Global Regulatory Perspectives:
    The journal provides insights into regulatory frameworks from various regions, facilitating a better understanding of international regulatory practices and their implications for drug development.
The journal has seen a rise in interest in several emerging themes that reflect the evolving landscape of therapeutic innovation and regulatory science. These themes are indicative of current challenges and advancements in the field.
  1. Integration of Digital Health Technologies:
    There is an increasing trend towards the exploration of digital health technologies and their implications for clinical trials and regulatory processes, highlighting the need for adaptation in regulatory frameworks.
  2. Use of Artificial Intelligence and Machine Learning:
    Research on the application of AI and ML in drug development and regulatory science is gaining traction, reflecting the industry's shift towards data-driven decision-making and predictive analytics.
  3. Patient Engagement and Experience:
    A growing emphasis on understanding patient engagement and incorporating patient experience data into regulatory submissions and clinical trial design is evident, showcasing a move towards more patient-centered research.
  4. Adaptive and Seamless Trial Designs:
    The exploration of adaptive and seamless trial designs continues to trend upward, with studies focusing on their implementation and benefits in accelerating drug development timelines.
  5. Global Regulatory Harmonization:
    There is a notable increase in research addressing the need for global regulatory harmonization, particularly in the context of multinational clinical trials and the complexities of varying regulations.

Declining or Waning

As the field of therapeutic innovation and regulatory science evolves, certain themes have shown signs of declining prominence in recent publications. This shift may reflect changes in research priorities, advancements in methodologies, or the saturation of previously explored topics.
  1. Traditional Clinical Trial Methodologies:
    There has been a noticeable decrease in focus on traditional clinical trial designs without adaptive or innovative elements, as the field moves towards more flexible and efficient trial methodologies.
  2. General Pharmacovigilance Reporting:
    While pharmacovigilance remains a critical area, detailed reports on general pharmacovigilance practices seem to be waning, potentially due to the increasing specificity and sophistication of safety assessment methodologies.
  3. Regulatory Frameworks for Established Drugs:
    Research examining regulatory frameworks for already established drugs has decreased, as the emphasis shifts towards innovative therapies and the regulatory challenges associated with them.
  4. Historical Comparisons of Regulatory Processes:
    Studies that focus solely on historical comparisons of regulatory processes across different time periods are becoming less frequent, as the focus shifts towards current practices and future innovations.

Similar Journals

Statistics in Biopharmaceutical Research

Bridging statistics and pharmaceutical science for impactful research.
Publisher: TAYLOR & FRANCIS INCISSN: 1946-6315Frequency: 4 issues/year

Statistics in Biopharmaceutical Research, published by Taylor & Francis Inc, is a premier journal that occupies a crucial space in the realms of Pharmaceutical Science and Statistics and Probability. With a robust impact factor affirmed by its Q1 rankings in both categories, the journal stands as a beacon for innovative statistical methodologies and their applications in biopharmaceutical research. Researchers and professionals will find a rich repository of high-quality articles that address contemporary challenges in drug development, clinical trials, and regulatory frameworks. Since its inception in 2011, the journal has continued to foster interdisciplinary collaboration, making significant strides towards enhancing statistical practice in biomedicine. With a commitment to academic rigor and practical relevance, Statistics in Biopharmaceutical Research is an essential resource for anyone looking to advance their understanding and application of statistical techniques in the pharmaceutical industry.

Contemporary Clinical Trials Communications

Advancing Clinical Research for a Healthier Tomorrow
Publisher: ELSEVIER INCISSN: Frequency:

Contemporary Clinical Trials Communications, published by ELSEVIER INC, serves as a pivotal resource in the evolving fields of medicine and pharmacology, especially with its commitment to open access since 2015. With the E-ISSN 2451-8654, this journal is dedicated to disseminating high-quality research that examines contemporary clinical trial methodologies and their applications in improving healthcare outcomes. Situated in the United States, its impressive ranking, with a Q2 status in both Medicine (miscellaneous) and Pharmacology for 2023, highlights its significance and impact within the scientific community. Ranking #199 out of 636 in General Medicine and #217 out of 313 in Pharmacology on the Scopus scale, the journal aims to foster innovative discussions and developments among researchers, professionals, and students, making it an essential tool for those seeking to stay at the forefront of clinical research and trials.

Reviews on Recent Clinical Trials

Bridging Disciplines in Clinical Trial Methodologies.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1574-8871Frequency: 4 issues/year

Reviews on Recent Clinical Trials, published by Bentham Science Publishers Ltd, is a distinguished journal in the medical and pharmacological fields, assessing the latest advancements in clinical research since its inception in 2006. With a focus on integrating multidisciplinary approaches to evaluating clinical trial methodologies, the journal caters to a diverse audience of researchers, professionals, and students keen on enhancing their knowledge and understanding of innovative therapeutic strategies and drug developments. Notably positioned in the Q3 quartile as ranked by Scopus for both 'Medicine (miscellaneous)' and 'Pharmacology', the journal illustrates a growing academic influence, evidenced by its Scopus rankings—holding a commendable 72nd percentile in general medicine and a 33rd percentile in pharmacology. While the journal is not open access, it remains committed to disseminating high-quality, peer-reviewed content that drives forward the conversation in clinical research. For those interested in staying abreast of novel findings and comprehensive reviews within the clinical trial landscape, Reviews on Recent Clinical Trials stands out as an essential resource.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Connecting research to clinical practice for better health outcomes.
Publisher: WILEYISSN: 1053-8569Frequency: 12 issues/year

Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.

Clinical Pharmacology in Drug Development

Transforming clinical practices with groundbreaking research.
Publisher: WILEYISSN: 2160-7648Frequency: 6 issues/year

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

PHARMACEUTICAL STATISTICS

Empowering Research with Statistical Insights in Pharmacology
Publisher: WILEYISSN: 1539-1604Frequency: 6 issues/year

PHARMACEUTICAL STATISTICS is a premier academic journal published by Wiley, focusing on the intersection of pharmacology and statistics. With the ISSN 1539-1604 and E-ISSN 1539-1612, this journal has established itself as a leading resource in the field since its inception in 2004, with a targeted convergence year extending to 2024. Notably, it ranks in the Q1 category for both pharmacology and statistics, reflecting its high impact and significance within these disciplines. The journal embraces a wide scope, encompassing statistical methodology and its application in pharmaceuticals, thus serving as an essential platform for researchers, professionals, and students committed to advancing their knowledge and practice. Its notable placement in Scopus rankings further reinforces its academic credibility, making it a valuable reference point for high-quality research. Although this journal does not currently offer open access options, it remains a vital source of insights and research advancements in the pharmaceutical sciences.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Transforming research into practice in clinical pharmacology.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Contemporary Clinical Trials

Transforming Ideas into Impactful Studies
Publisher: ELSEVIER SCIENCE INCISSN: 1551-7144Frequency: 6 issues/year

Contemporary Clinical Trials, published by Elsevier Science Inc, stands at the forefront of clinical research, providing a dedicated platform for the dissemination of innovative studies and methodologies in medicine and pharmacology. With an impressive impact factor reflecting its consistent contributions to the field, this journal is categorized in the Q1 quartile for both Medicine (miscellaneous) and Pharmacology (medical) as of 2023. The journal's scope encompasses a broad range of topics pertinent to clinical trial design, execution, and analysis, aiming to enhance the effectiveness and safety of therapeutic interventions. Operating under an Open Access model, it ensures that the latest research is accessible to a global audience, fostering collaboration and discussion among researchers, professionals, and students alike. In publishing high-quality articles since its inception in 2005, Contemporary Clinical Trials continues to shape the future of clinical research with its commitment to excellence and innovation.

CURRENT GENE THERAPY

Transforming Genetic Horizons.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1566-5232Frequency: 6 issues/year

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.

CPT-Pharmacometrics & Systems Pharmacology

Empowering researchers with open access to vital pharmacometric knowledge.
Publisher: WILEYISSN: 2163-8306Frequency: 12 issues/year

CPT-Pharmacometrics & Systems Pharmacology, published by WILEY, is a leading open access journal dedicated to advancing the fields of pharmacometrics and systems pharmacology. Since its inception in 2012, it has established itself as a vital resource for researchers and practitioners, boasting a remarkable impact factor and occupying prestigious Q1 quartiles in categories such as Cardiology and Cardiovascular Medicine, Modeling and Simulation, and Pharmacology (Medical). The journal covers a broad spectrum of topics aimed at enhancing the understanding of drug development, efficacy, and patient safety through innovative modeling and simulation approaches. With its consistent ranking in the top tiers of its field, CPT-Pharmacometrics & Systems Pharmacology provides invaluable insights and fosters scholarly dialogue among its audience, including researchers, educators, and students. The journal is accessible to all, promoting knowledge dissemination and collaborative growth in the pharmacology community.